Abstract
BackgroundAnti-PD-1 therapy is increasingly used in various advanced malignancies. Patients with baseline organ dysfunction are largely excluded from clinical trials. Therefore it is unclear whether anti-PD-1 therapy is safe or...
Highlights
Anti-Programmed death receptor 1 (PD-1) therapy is increasingly used in various advanced malignancies
These agents, including nivolumab and pembrolizumab, have produced objective responses, many of which are durable, in numerous solid and hematologic malignancies [1,2,3,4,5,6,7,8]. As these agents are incorporated into standard treatment algorithms, questions have arisen regarding their use in patient populations excluded from clinical trials, including those with organ dysfunction
Most patients were male with a median age of 69, and a majority received nivolumab as their anti-PD-1 therapy
Summary
Patients with baseline organ dysfunction are largely excluded from clinical trials It is unclear whether anti-PD-1 therapy is safe or effective in this setting. Agents that block the interaction between programmed death-1 receptor and its ligand (PD-1/PD-L1) inhibit this negative immune regulator and thereby unleash antitumor immune responses These agents, including nivolumab and pembrolizumab, have produced objective responses, many of which are durable, in numerous solid and hematologic malignancies [1,2,3,4,5,6,7,8]. Monoclonal antibodies bound to protective receptors are protected from degradation, explaining their exceptionally long half-lives [10]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
